イイダ　トモヒロ   IIDA Tomohiro   飯田　知弘    所属   医学部 医学科（東京女子医科大学病院）    職種   客員教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan.
掲載誌名	正式名：Scientific reports 略　 称：Sci Rep ISSNコード：20452322/20452322
掲載区分	国外
巻・号・頁	14(1),pp.11681
著者・共著者	Mukai Ryo, Kataoka Keiko, Tanaka Koji, Miyara Yasunori, Maruko Ichiro, Nakayama Makiko, Watanabe Yuto, Yamamoto Akiko, Wakatsuki Yu, Onoe Hajime, Wakugawa Sorako, Terao Nobuhiro, Hasegawa Taiji, Kawai Moeko, Maruko Ruka, Itagaki Kanako, Honjo Jyunichiro, Okada Annabelle A, Mori Ryusaburo, Koizumi Hideki, Iida Tomohiro, Sekiryu Tetsuju
発行年月	2024/05
概要	This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Fifty-five patients (57 eyes) underwent loading therapy comprising three monthly faricimab injections. If dryness was achieved by the third month, subsequent treat-and-extend (TAE) follow-up continued at a minimum 8-week interval thereafter. If wet macula persisted at the third month, a fourth dose was administered, followed by the TAE regimen. After 1 year, improvements in visual acuity (0.44 ± 0.46 [baseline] to 0.34 ± 0.48; p < 0.01) and central foveal thickness (326 ± 149 [baseline] to 195 ± 82 μm; p < 0.0001) were significant. Dry macula, characterised by the absence of intraretinal or subretinal fluid, was achieved in 65% of cases. Treatment intervals varied, ranging from 8 to 16 weeks, with 44% of eyes extending to a 16-week interval, followed by 33% at 8 weeks, 16% at 12 weeks, 5% at 14 weeks, and 2% at 10 weeks. Notably, 50% of the polypoidal choroidal vasculopathy patients exhibited complete regression of polypoidal lesions between 12 and 15 months. Faricimab treatment in nAMD patients induced significant improvements in central vision and retinal morphology. Two cases of retinal pigment epithelial tears and one case of iritis were reported as ocular complications.
DOI	10.1038/s41598-024-62559-1
PMID	38778065